In a report issued on May 9, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (URGN). The company’s shares closed on Friday at $39.34, close to its 52-week low of $34.61.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.7% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma Ltd with a $66.25 average price target, a 68.4% upside from current levels. In a report issued on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $75 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.57 and a one-year low of $34.61. Currently, Urogen Pharma Ltd has an average volume of 121.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.